臺灣博碩士論文加值系統

本論文之主題在於建立毛細管電泳法 ( capillary electrophoresis , CE )對多種抗痛風及降尿酸藥物之同時定量分析。首先探討區帶毛細管電泳法 (capillary zone electrophoresis) 對allopurinol、benzbromarone、orotic acid、oxypurinol、probenecid、sulfinpyrazone及colchicine 七種藥物之同時分析。初步結果顯示，在硼酸鹽緩衝溶液 ( 50 mM ; pH 9.00 )，使用15 kV的分離電壓，偵測波長為214 nm條件下，除了colchicine外，能分離其餘六種待測物，且具定量性，其定量範圍均在20 - 100 μM。進而利用微胞電動毛細管層析法( micellar electrokinetic chromatography, MEKC ) 分別針對上述七種待測物進行同時分析研究。結果顯示以硼酸鹽緩衝溶液 ( 45 mM; pH 9.00 )、20 mM sodium dodecyl sulfate ( SDS )，使用20 kV的分離電壓，偵測波長為214 nm，能分離上述等七種待測物。其中allopurinol、oxypurinol、orotic acid及probenecid定量範圍在10–200 μM，benzbromarone、colchicine、sulfinpyrazone定量範圍則為5-200 μM。偵測極限 (limit of detection) : allopurinol 2.0 μM; benzbromarone 0.6 μM； colchicine 0.9 μM；orotic acid 4.0 μM； oxypurinol 1.0 μM；probenecid 3.0 μM及 sulfinpyrazone 0.8 μM ( S/N=3，0.5 psi，注射5秒)。本法之準確度與精密度其R.S.D.及R.E. 均小於4 %，本法已成功應用於市售製劑allopurinol及colchicine之含量分析。

Capillary electrophoresis method (CE) was studied for the simultaneous separation and quantitation of seven antigout and uricosuric drugs including allopurinol (AP), benzbromarone (BZB), orotic acid (OA), oxypurinol (OP), probenecid (PB) and sulfinpyrazone (SPZ).
Capillary zone electrophoresis method (CZE) was first tried to the separation of the seven drugs. At the conditions of background electrolyte with borate buffer (50 mM; pH 9.00), applied voltage of 15 kV, untreated fused-silica capillary (40.2 cm, effective length 30 cm, 50 μm I.D.), hydrodynamic injection (0.5 psi, 5 s) and detection at 214 nm, CZE can separate and quantitate six drugs excluding colchicine with a quantitative range of 20-100 μM.
Further application of micellar electrokinetic chromatography (MEKC) to the separation of the seven drugs was performed. The results indicate that MEKC can separate and quantities all the seven drugs including colchicine at the conditions of borate buffer (45 mM; pH 9.00) with 20 mM sodium dodecyl sulfate and other CE conditions similar to those used in CZE. On the method validation, the calibration curves were linear over a range of 5-200 μM for benzbromarone, sulfinpyrazone and colchicine and 10-200 μM for allopurinol, orotic acid, oxypurinol and probenecid, respectively (r > 0.999). The RSD and RE were all less than 4 % for the intraday and interday assay. All the recoveries were greater than 96 %. The limits of detection were 2.0 μM for allopurinol, 0.6 μM for benzbromarone, 0.9 μM for colchicine, 4.0 μM for orotic acid, 1.0 μM for oxypurinol, 3.0 μM for probenecid, and 0.8 μM for sulfinpyrazone (S/N=3, 0.5 psi, 5s). Partial application of the method to the determination of allopurinol and colchicine in commercial tablets proved feasible.

中文摘要--------------------------------------------------------------------- і
英文摘要--------------------------------------------------------------------- іі
目錄--------------------------------------------------------------------------- ііі
圖目錄------------------------------------------------------------------------ vіі
表目錄------------------------------------------------------------------------ ix
第壹章 緒論 --------------------------------------------------------------- 1
一、待測物簡介------------------------------------------------------- 1
二、待測物分析法回顧---------------------------------------------- 4
三、毛細管電泳之簡介---------------------------------------------- 8
四、研究目的---------------------------------------------------------- 15
第貳章 實驗材料及儀器-------------------------------------------------- 16
一、儀器---------------------------------------------------------------- 16
二、試藥及材料------------------------------------------------------- 16
三、毛細管電泳分析條件------------------------------------------- 18
四、試藥溶液之配製------------------------------------------------- 19
1. 區帶毛細管電泳法對抗痛風及降尿酸劑之分析------- 19
2. 微胞電動毛細管層析法對抗痛風及降尿酸劑之分析 21

第参章 區帶毛細管電泳法對抗痛風及降尿酸劑之分析----------- 25
一、基本分析條件之探討---------------------------------------- 25
1. 選擇適當偵測波長----------------------------------------- 25
2. 待測物之個別定位------------------------------------------ 25
3. 緩衝溶液濃度之選擇--------------------------------------- 25
4. 緩衝溶液pH之選擇---------------------------------------- 26
5. 分析電壓大小選擇------------------------------------------ 26
二、基本分析法之驗證----------------------------------------------- 26
1. 定量性--------------------------------------------------------- 26
三、結果與討論------------------------------------------------------- 27
1 基本分析條件之建立----------------------------------------- 27
(1) 選擇適當偵測波長--------------------------------------- 27
(2) 緩衝溶液濃度之選擇------------------------------------ 29
(3) 緩衝溶液pH之選擇------------------------------------- 32
(4) 分析電壓大小選擇--------------------------------------- 35
2 基本分析條件之驗證----------------------------------------- 38
(1) 藥物檢量線之建立--------------------------------------- 38
3 毛細管電泳法加入CD addictives對分析之影響------- 40


第肆章 微胞電動毛細管層析法對抗痛風及降尿酸劑之分析---- 45
一、基本分析條件之探討-------------------------------------------- 45
1. 七種待測物之個別定位------------------------------------ 45
2. 緩衝液濃度之探討------------------------------------------ 45
3. SDS 濃度之選擇-------------------------------------------- 45
4. 緩衝溶液pH之選擇---------------------------------------- 45
5. 分析電壓之探討--------------------------------------------- 46
二、基本分析法之驗證----------------------------------------------- 46
1. 七種待測物之定量性--------------------------------------- 46
2. 分析方法精密度及準確度之探討------------------------ 47
(1) 同日間分析--------------------------------------------- 47
(2) 異日間分析--------------------------------------------- 47
3. 市售allopurinol及colchicine製劑回收率之探討----- 48
三、應用分析--------------------------------------------------------- 50
1. 市售allopurinol及colchicine製劑之含量分析-------- 50
2. 市售colchicine製劑之含量均ㄧ度分析---------------- 51
四、結果與討論------------------------------------------------------- 51
1 基本分析條件之探討--------------------------------------- 51
(1) 緩衝液濃度之探討------------------------------------ 51
(2) SDS 濃度之選擇------------------------------------ 54
(3) 緩衝溶液pH之選擇---------------------------------- 56
(4) 分析電壓大小選擇------------------------------------ 59
2 基本分析法之驗證----------------------------------------- 63
(1) 定量性--------------------------------------------------- 63
(2) 分析方法精密度及準確度之探討------------------ 65
Ⅰ同日間分析------------------------------------------ 65
Ⅱ異日間分析------------------------------------------ 65
3 市售allopurinol及colchicine製劑回收率之探討------ 68
4 應用分析------------------------------------------------------ 69
(1) 市售allopurinol及colchicine製劑含量分析------ 69
(2) 市售colchicine製劑之含量均ㄧ度分析----------- 71
五、 結論-------------------------------------------------------------- 72
第伍章 參考文獻----------------------------------------------------------- 73

1R.A. Terkeltaub, Gout, N. Engl. J. Med, 349, 17(2003) 1647-1655.
2K.Y. Kim, H.R. Schumacher, E. Hunsche, A.I. Wertheimer, S.X. Kong, A literature review of the epidemiology and treatment of acute gout, Clin. Ther.,25(2003) 1593-1617.
3B.T. Emmerson, The management of gout, N. Engl. J. Med, 334(1996) 445-451.
4J.D. Wright, A.B. Pinto, Clinical manifestations and treatment of gout, Prim Care Update Ob/Gyns, 10 (2003) 19-23.
5J.G. Hardaman, L.E. Limbird (Eds.), The Pharmacological Basis of Therapeutics (Goodman and Gilman’s), 10th ed., Pergamon, New York, 2001, 719-727.
6R.L. Wormann, Effective Management of Gout: An Analogy, Am. J. Med, 105(1998) 513-514.
7T. R. Keith, C. A. Agudelo, Gout, JAMA, 349, 21(2003) 2857-2860.
8M. Windholz, S. Blumetti, Merck Index, Merck & CO., Inc., 13th ed., 2001.
9D.A. Williams, T.L. Lemke, Foye’s Principles of Medicinal Chemistry, 5 th ed. edition, 1078.
10J. N. Delgado, W. A. Remers, Wilson and Gilvold’s Textbook of Organic Medicinal and Pharmaceutical Chemistry, 10 th ed., 915-919.
11K. Safranow, Z. Machoy, K. Ciechanowski, Analysis of purines in urinary calculi by High-Performance Liquid Chromatography, Anal. Chem., 286(2000) 224-230.
12A. Gumieniczek, I. Przyborowski, Determination of Benzbromarone and Benzarone in pharmaceuticals by high-performance liquid chromatography, J. Liq. Chromatogr., 17(1994) 3411-3419.
13A. S. Akalin, S. Gonc, Y. Akbas, Variation in organic acids content during ripening of pickled white cheese, J. Dairy Sci., 85(2002) 1670-1676.
14H. Hernandez, P. C. Falco, A. S. Cabeza, Review. Estimation of diuretic drugs in biological fluids by HPLC, Chromatographia,33 (1992) 177-184.
15A. berthod, J. J. Laserna, I. Carretero, Oil-in-water microemulsions as mobile phases for rapid screening of illegal drugs in sports, J. Liq. Chromatogr., 15(1992) 3115-3127.
16P. C. Falco, R. H. Hernandez, A.S. Cabeza, Sensitive determination of probenecid in urine samples by reversed-phase liquid chromatography and UV-Visible detection using solid-phase extraction techniques for sample clean-up, Chromatographia, 35 (1993) 317-320.
17P. Branditt, Determination of orotic acid in serum by high-performance liquid chromatography, J. Chromatogr. B, 660(1994) 176-179.
18E. L. Palylyk, F. Jamali, Simultaneous determination of ketoprofen enantiomers and probenecid in plasma and urine by high-performance liquid chromatography, J. Chromatogr., 568 (1991) 187-196.
19T.B. Vree, M. Martea, C.P.W.G.M. V. Wissen, Determination of furosemide with its acyl glucoronide in human plasma and urine by means of direct gradient high performance liquid chromatographic analysis with fluorescence detection. Preliminary pharmacokinetics and effect of probenecid, J. Chromatogr. B, 655 (1994) 53-62
20P. J. Arnold, R. Guserle, V. Luckow, Liquid chromatography-mass spectrometry in metabolic research, J. Chromatogr. , 544(1991) 267-280.
21W. Li, Y. Sun, J. F. Fitzloff, Richard B. v. Breemen, Evaluation of commercial Ginkgo and Echinacea dietary supplements for colchicine using liquid chromatography-tandom mass spectrometry, Chem. Res. Toxicol, 15(2002) 1174-1178.
22A. Tracqui, P. Kintz, B. Ludes, C. Rouge, H. Douibi, P. Mangin, High-performance liquid chromatography coupled to ion spray mass spectrometry for the determination of colchicine at ppb levels in human biofluids, J. Chromatogr. B, 675(1996) 235-242.
23U.S. Pharmacopeia 25-National Formulary 20, Asianedition,2002, Revision, United States Pharmacopeial Convention,Allopurinol, 62-63, Colchicine 473, Probenecid 1440.
24P. Tomas, M. Carmen, V. Tomas, R. Galera, Development of a capillary electrophoresis method for the determination of allopurinol and its active metabolite oxypurinol, J. Chromatogr. B, 798(2003) 303-308.
25M. L. Riekkola, J. H. Jumppanen, Review. Capillary electrophoresis of diuretics, J. Chromatogr. A, 735(1996) 151-164.
26U. Jegle, Separation of water-soluble vitamins via high performance capillary electrophoresis, J. Chromatogr. A, 652(1993)495-501.
27Z.K. Shihabi, M.E. Hinsdale, A.J. Bleyer, Xanthine analysis in biological fluids by capillary electrophoresis, J. Chromatogr. B, 669(1995) 163-169.
28C. J. Petucci, H. L. Kantes, T. G. Strein, H. Veening, Capillary electrophoresis as a clinical tool, Determination of organic anions in normal and uremic serum using photodiode-array detection. J. Chromatogr. B, 668(1995) 241-251.
29T. Wessel, C. Lanvers, S. Fruend, G. Hempel, Determination of purines including 2,8-dihydroxyadenine in urine using capillary electrophoresis, J. Chromatogr. A, 894 (2000) 157-164.
30X. Sun, W. Cao, X. Bai, X. Yang, E. Wang, Determination of allopurinol and its active metabolite oxypurinol by capillary electrophoresis with end-column amperometric detection. Anal. chim. Acta., 442(2001) 121-128.
31M. Dankova, S. Strasik, M. Molnarrova, D. Kaniansky, J. Marak, Capillary zone electrophoresis of orotic acid in urine with online isotachophoresis sample pretreatment and diode array detection, J. Chromatogr. A, 916(2001) 143-153.
32F. Alali, K. T. Rana , M. Qasaymeh, Determination of colchicine in Colchicum steveni and C. hierosolymitanum (Colchicaceae): Comparison between two analytical methods, Phytochem. Anal., 15(2004) 27-29.
33T. H. Tsai, Analytical approaches for traditional Chinese medicine exhibiting antineoplastic activity, J. Chromatogr. B, 764 (2001) 27-48.
34P.A. Evrard, C. Ragusi, G. Boschi, R.K. Verbeeck, J.M. Scherrmann, Brain Res. 786 (1998) 122-127.
35S. Desrayaud, R. Guntz, J.M. Scherrmann, M. Lemaire, Life Sci.61 (1994) 153-163.
36A. S. Douglas, F. J. Holler, A. N. Timothy, Principles of Instrumental Analysis, Fifth Edition, Harcourt, 1997 , 778-784.
37Introduction to Capillary Electrophoresis, Modes of capillary electrophoresis, Beckman, 2-31.
38S. Terabe, Micellar Electrokinetic Chromatography, Beckman, 1-6.
39H. Nishi, S. Terabe, Review Micellar electrokinetic chromatography Perspectives in drug analysis, J. Chromatogr. A, 735(1996)3-27.
40S. Fanali, Z. Aturki, C. Desiderio, New strategies for chiral analysis of drugs by capillary electrophoresis, Forensic Sci. Int., 92 (1998) 137-155.